VNDA
Vanda Pharmaceuticals Inc
NASDAQ: VNDA · HEALTHCARE · BIOTECHNOLOGY
$6.27
-3.52% today
Updated 2026-06-05
Market cap
$366.83M
P/E ratio
—
P/S ratio
1.68x
EPS (TTM)
$-4.06
Dividend yield
—
52W range
$4 – $10
Volume
1.1M
WallStSmart proprietary scores
37
out of 100
Grade: D
Sell
Investment rating
2.7
Growth
F6.0
Quality
B2.0
Profitability
F6.3
Valuation
B2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$14.90
+137.64%
12-Month target
—
—
Intrinsic (DCF)
$37.46
Margin of safety
+83.66%
0 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ 83.66% below intrinsic value
+ Debt/equity 0.05x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z 0.00 — distress zone
- Thin margins at -110.00%
- Negative free cash flow $-50.44M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $254.38M | $192.64M | $198.77M | $216.10M | $217.78M |
| Net income | $6.28M | $2.51M | $-18.90M | $-220.47M | $-48.57M |
| EPS | — | — | — | — | $-4.06 |
| Free cash flow | $31.30M | $12.42M | $-16.25M | $-110.44M | $-50.44M |
| Profit margin | 2.47% | 1.30% | -9.51% | -102.02% | -110.00% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-22 | DUNCAN, CHARLES CLIFF | Buy | 57,101 | — |
| 2026-03-02 | WILLIAMS, TIMOTHY | Sale | 42,434 | $8.27 |
| 2026-03-02 | WIJKSTROM, JOAKIM | Sale | 30,800 | $8.27 |
Peer comparison
Smart narrative
Vanda Pharmaceuticals Inc trades at $6.27. Our Smart Value Score of 37/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. TTM revenue stands at $217.78M. with profit margins at -110.00%. Our DCF model estimates intrinsic value at $37.46.
Frequently asked questions
What is Vanda Pharmaceuticals Inc's stock price?
Vanda Pharmaceuticals Inc (VNDA) trades at $6.27, on a P/S of 1.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Vanda Pharmaceuticals Inc overvalued?
Vanda Pharmaceuticals Inc carries a Smart Value Score of 37/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $37.46 versus the $6.27 price, a 83.7% margin of safety on a cash flow basis.
What is the price target of Vanda Pharmaceuticals Inc (VNDA)?
The 12-month analyst consensus target is $14.90, about 137.6% above the current $6.27. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Vanda Pharmaceuticals Inc (VNDA)?
Our DCF model estimates intrinsic value at $37.46, a +83.7% margin of safety versus today's $6.27. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Vanda Pharmaceuticals Inc's revenue?
Vanda Pharmaceuticals Inc's trailing twelve-month revenue is $217.78M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.68x
ROE-60.50%
Beta0.60
50D MA$6.68
200D MA$6.37
Shares out0.06B
Float0.05B
Short ratio—
Avg volume1.1M
Performance
1 week-16.93%
1 month-13.02%
3 months-16.38%
YTD-28.80%
1 year—
3 years—
5 years—